Recent Company News

• 09:18 AM ET Oct 13, 2026
  

  StreetAccount Summary - US Pre-market trading update

• 08:51 AM ET Oct 13, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:21 AM ET Oct 13, 2026
  

  StreetAccount Summary - US Pre-market trading

• 06:49 AM ET Oct 13, 2026
  

  BioNTech announces AHEAD-MERIT Phase 2/3 clinical trial for BNT113 did not meet first dual primary endpoint of PFS; trial will continue to evaluate second dual primary endpoint of OS ($95.84, 0.00)

• 07:48 PM ET Oct 09, 2026
  

  StreetAccount Sector Summary - Healthcare Weekly Recap

• 01:03 PM ET Oct 09, 2026
  

  Cancer Vaccines Are the NIH's Next 'Big Bet' - NY Times

• 08:57 AM ET Oct 08, 2026
  

  BioNTech initiated hold at Argus Research ($95.25, 0.00)

• 04:54 PM ET Sep 28, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 09:26 AM ET Sep 28, 2026
  

  BioNTech to shutter sites in Germany, Singapore as no buyers emerge - Reuters ($98.52, 0.00)

• 01:32 PM ET Sep 17, 2026
  

  Health Canada authorizes Pfizer and BioNTech's Omicron XFG-adapted COVID-19 Vaccine ($27.64, +0.18)